Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Hot
News

Facebook To Start Trading Under Ticker ‘MVRS’ Starting Dec. 1

-Bloomberg

byBenzinga Newsdesk

October 28, 2021

1 minute read

-Bloomberg

Shockwave Medical Raises FY21 Sales Guidance From $195M-$205M To $218M-$223M vs $200.64M Est.

By Bill Haddad

August 9, 7:38 AM

Shockwave Medical projects revenue for the full year 2021 to range from $218 million to $223 million, which represents 222% to 229% growth over the company's prior year revenue.

SWAV

Fed’s Powell’s Testimony Submitted To House Financial Services Committee Repeats Written Remarks To Senate Banking Committee

By Happy Mohamed

March 8, 9:55 AM

- Reuters

SPY

FDA
News

Genmab And AbbVie Announce Topline Results For Epcoritamab From Phase 1/2 Trial In Patients With Relapsed/Refractory Large B-Cell Lymphoma

By Benzinga Newsdesk

April 13, 5:31 PM

Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2, clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an

ABBV

Morgan Stanley Maintains Overweight on Regions Financial, Raises Price Target to $28

By Benzinga Newsdesk

December 16, 10:12 AM

Morgan Stanley analyst Betsy Graseck maintains Regions Financial (NYSE:RF) with a Overweight and raises the price target from $27 to $28.

Facebook To Start Trading Under Ticker ‘MVRS’ Starting Dec. 1

Related Posts

Shockwave Medical Raises FY21 Sales Guidance From $195M-$205M To $218M-$223M vs $200.64M Est.

Fed’s Powell’s Testimony Submitted To House Financial Services Committee Repeats Written Remarks To Senate Banking Committee

Genmab And AbbVie Announce Topline Results For Epcoritamab From Phase 1/2 Trial In Patients With Relapsed/Refractory Large B-Cell Lymphoma

Morgan Stanley Maintains Overweight on Regions Financial, Raises Price Target to $28